Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works

Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis

Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · see citing works

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial

Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · see citing works

Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance

Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 938 · see citing works

Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity

Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886 · see citing works

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · see citing works

Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.

Bergman, R. N., Prager, R., Volund, A., & Olefsky, J. M. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112886 · Cited by 772 · see citing works

Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)

Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · see citing works

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

DeFronzo, R. A., Norton, L., & Abdul‐Ghani, M. A. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 556 · see citing works

High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels

Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503 · see citing works

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367 · see citing works

Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action

Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341 · see citing works

Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial

Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 280 · see citing works

Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V., Hardies, J., & Cusi, K. J. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 253 · see citing works

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151511 · Cited by 230 · see citing works

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225 · see citing works

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., & Aso, Y. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0169-x · Cited by 202 · see citing works

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195 · see citing works

Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study

Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 192 · see citing works

Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis

Bril, F., Lomonaco, R., Orsak, B., Ortiz‐Lopez, C., Webb, A., Tio, F. O., Hecht, J., & Cusi, K. J. (2013) · Hepatology · doi:10.1002/hep.26988 · Cited by 173 · see citing works

Nonalcoholic Fatty Liver Disease

Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 153 · see citing works

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

Lomonaco, R., Bril, F., Portillo-Sánchez, P., Ortiz‐Lopez, C., Orsak, B., Biernacki, D., Lo, M. C., Suman, A., Weber, M. H., & Cusi, K. J. (2016) · Diabetes Care · doi:10.2337/dc15-1876 · Cited by 150 · see citing works

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum

Cefalu, W. T., Buse, J. B., Tuomilehto, J. O., Fleming, G. A., Ferrannini, E., Gerstein, H. C., Bennett, P. H., Ramachandran, A., Raz, I., Rosenstock, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0873 · Cited by 143 · see citing works

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.07.002 · Cited by 141 · see citing works

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 127 · see citing works

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., Mori, K., Matsunaga, Y., Yamamotoya, T., Kamata, H., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0102-8 · Cited by 113 · see citing works

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

Hayashizaki, Y., Kurosaki, E., Takasu, T., Mitori, H., Yamazaki, S., Koide, K., & Takakura, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.009 · Cited by 108 · see citing works

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

Suzuki, M., Takeda, M., Kito, A., Fukazawa, M., Yata, T., Yamamoto, M., Nagata, T., Fukuzawa, T., Yamane, M., Honda, K., et al. (2014) · Nutrition and Diabetes · doi:10.1038/nutd.2014.20 · Cited by 97 · see citing works

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice

Wang, D., Luo, Y., Wang, X., Orlicky, D. J., Myakala, K., Yang, P., & Levi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010137 · Cited by 95 · see citing works

Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

Nakano, S., Katsuno, K., Isaji, M., Nagasawa, T., Buehrer, B. M., Walker, S., Wilkison, W. O., & Cheatham, B. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.005 · Cited by 82 · see citing works

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70 · see citing works

Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes

Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56 · see citing works

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats

Nishimura, N., Kitade, M., Noguchi, R., Namisaki, T., Moriya, K., Takeda, K., Okura, Y., Aihara, Y., Douhara, A., Kawaratani, H., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1200-6 · Cited by 44 · see citing works

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

Cusi, K. J., Sanyal, A. J., Zhang, S., Hoogwerf, B. J., Chang, A. M., Jacober, S. J., Bue-Valleskey, J. M., Higdon, A. N., Bastyr, E. J., Haupt, A., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12751 · Cited by 40 · see citing works

Quantitation of Monosaccharide Isotopic Enrichment in Physiologic Fluids by Electron Ionization or Negative Chemical Ionization GC/MS Using Di-O-isopropylidene Derivatives

Hachey, D. L., Parsons, W. R., McKay, S. V., & Haymond, M. W. (1999) · Analytical Chemistry · doi:10.1021/ac990724x · Cited by 35 · see citing works

Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

Portillo-Sánchez, P., Yavuz, S., Bril, F., & Cusi, K. J. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0229-3 · Cited by 25 · see citing works

Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes

Kusunoki, M., Natsume, Y., Sato, D., Tsutsui, H., Miyata, T., Tsutsumi, K., Suga, T., & Oshida, Y. (2016) · Drug Research · doi:10.1055/s-0042-111515 · Cited by 19 · see citing works

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · see citing works

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · see citing works

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Eslam, M., Sarin, S. K., Wong, V. W., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M., Shiha, G. E.-S., Yilmaz, Y. N., Gani, R. A., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 837 · see citing works

Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review

Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776 · see citing works

Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease

Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618 · see citing works

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 507 · see citing works

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455 · see citing works

Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial

Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360 · see citing works

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans

Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330 · see citing works

Insulin resistance and insulin sensitizing agents

Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 259 · see citing works

The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

Caussy, C., Aubin, A., & Loomba, R. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01383-7 · Cited by 246 · see citing works

Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K. J., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 233 · see citing works

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review

Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025

ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M. S., Balapattabi, K., Beverly, E. A., Early, K. B., Bruemmer, D., Cusi, K. J., Echouffo-Tcheugui, J. B., et al. (2024) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 222 · see citing works

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 193 · see citing works

Management of non-alcoholic fatty liver disease

Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 181 · see citing works

Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach

Chew, N., Mehta, A., Goh, R. S. J., Zhang, A. A. Y., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A. C., Dimitriadis, G. K., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 185 · see citing works

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 186 · see citing works

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

Targher, G., Corey, K. E., & Byrne, C. D. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 170 · see citing works

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works

Metabolic liver disease in diabetes – From mechanisms to clinical trials

Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 160 · see citing works

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024

ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 167 · see citing works

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Arab, J. P., Dirchwolf, M., Álvares‐da‐Silva, M. R., Francisco Barrera, M., Benítez, C., Castellanos, M., Castro‐Narro, G., Chávez-Tapia, N. C., Chiodi, D., Cotrim, H. P., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.09.006 · Cited by 142 · see citing works

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138 · see citing works

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Pοlyzos, S. A., Kang, E. S., Boutari, C., Rhee, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154203 · Cited by 139 · see citing works

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 136 · see citing works

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 130 · see citing works

Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications

Byrne, C. D., & Targher, G. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14484 · Cited by 122 · see citing works

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Kullmann, S., Hummel, J., Wagner, R. J., Dannecker, C., Vosseler, A., Fritsche, L., Veit, R., Kantartzis, K., Machann, J., Birkenfeld, A. L., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1136 · Cited by 112 · see citing works

Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!

Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 108 · see citing works

Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025

Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 102 · see citing works

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100 · see citing works

Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD

Barb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Dzen, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.045 · Cited by 91 · see citing works

Management of NAFLD in primary care settings

Wong, V. W., Zelber‐Sagi, S., Cusi, K. J., Carrieri, P., Wright, E. E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 82 · see citing works

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Rossing, P. R., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P. P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00295-3 · Cited by 77 · see citing works

SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease

Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 75 · see citing works

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association

Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 77 · see citing works

Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74 · see citing works

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes

Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 69 · see citing works

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 68 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 86 · see citing works

Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH

Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66 · see citing works

SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD

Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 71 · see citing works

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

den Kamp, Y. J. M. O., de Ligt, M., Dautzenberg, B., Moonen‐Kornips, E., ESTERLINE, R. L., Hesselink, M. K. C., Joris Hoeks, J., Schrauwen‐Hinderling, V. B., Havekes, B., Oscarsson, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2887 · Cited by 63 · see citing works

Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials

Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61 · see citing works

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61 · see citing works

The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment

Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 63 · see citing works

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?

Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 56 · see citing works

Diabetes as a risk factor for MASH progression

Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 59 · see citing works

Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial

Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 56 · see citing works

Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease

Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 55 · see citing works

Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

Cusi, K. J. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52 · see citing works

Metabolic syndrome and its association with nonalcoholic steatohepatitis

Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52 · see citing works

The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment

Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 52 · see citing works

A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

Cusi, K. J. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 52 · see citing works

Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class

Kaneto, H., Obata, A., Kimura, T., Shimoda, M., Kinoshita, T., Matsuoka, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063062 · Cited by 48 · see citing works

SGLT2 Inhibitors in Liver Patients

Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48 · see citing works

Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials

Mori, Y., Duru, O. K., Tuttle, K. R., Fukuma, S., Taura, D., Harada, N., Inagaki, N., & Inoue, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac591 · Cited by 47 · see citing works

Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease

Pοlyzos, S. A., Goulis, D. G., Γιουλεμέ, Ό., Germanidis, G. S., & Goulas, A. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00474-0 · Cited by 46 · see citing works

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 50 · see citing works

Liver-targeting drugs and their effect on blood glucose and hepatic lipids

Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 46 · see citing works

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis

Colosimo, S., Ravaioli, F., Petroni, M. L., Brodosi, L., Marchignoli, F., Barbanti, F. A., Sasdelli, A. S., Marchesini, G., & Pironi, L. (2021) · Liver International · doi:10.1111/liv.14799 · Cited by 47 · see citing works

The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials

Bica, I.-C., Stoica, R. A., Salmen, T., Janež, A., Volčanšek, Š., Popovic, D. S., Muzurović, E. M., Rizzo, M., & Stoian, A. P. (2023) · Medicina · doi:10.3390/medicina59061136 · Cited by 42 · see citing works

Uncoupling hepatic insulin resistance – hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes

NIRANJAN, S., Phillips, B. E., & Giannoukakis, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1193373 · Cited by 43 · see citing works

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Rossing, P. R., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., et al. (2022) · UCL Discovery (University College London) · Cited by 40 · see citing works

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial

Yoneda, M., Kobayashi, T., Honda, Y., Ogawa, Y., Kessoku, T., Imajo, K., Nogami, A., Taguri, M., Kirikoshi, H., Saito, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1993 · Cited by 39 · see citing works

Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines

Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 49 · see citing works

Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment

Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 42 · see citing works

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS

Borisov, A. N., Kutz, A., Christ, E., Heim, M. H., & Ebrahimi, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad249 · Cited by 37 · see citing works

Impact of NAFLD and its pharmacotherapy on lipid profile and CVD

Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 37 · see citing works

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

Katsiki, N., Perakakis, N., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.07.009 · Cited by 36 · see citing works

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35 · see citing works

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 33 · see citing works

Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes

Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Brown, M., Clarke, G., Larvenenko, O., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-1646 · Cited by 37 · see citing works

SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach

McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 34 · see citing works

Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases

Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 33 · see citing works

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients

Brodosi, L., Petta, S., Petroni, M. L., Marchesini, G., & Morelli, M. C. (2021) · Transplantation · doi:10.1097/tp.0000000000003867 · Cited by 34 · see citing works

Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease

Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 32 · see citing works

Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease

Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 31 · see citing works

Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025

Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30 · see citing works

Metabolic reprogramming of immune cells in MASH

Ma, C., Wang, S., Dong, B., & Tian, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001371 · Cited by 32 · see citing works

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease

Kanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 35 · see citing works

Updates in Metabolic Dysfunction‐Associated Fatty Liver Disease (MAFLD) in Children

Rupasinghe, K., Hind, J. M., & Hegarty, R. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003919 · Cited by 27 · see citing works

NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 27 · see citing works

Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review

Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 28 · see citing works

The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease

Chrysavgis, L., Papatheodoridi, A., Chatzigeorgiou, A., & Cholongitas, Ε. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15202 · Cited by 26 · see citing works

At the Crossroads of Health and Disease: Consequences of Fat in the Liver

Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 28 · see citing works

Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies

Diaconu, C.-T., & Guja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175144 · Cited by 28 · see citing works

Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease

Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 24 · see citing works

Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent

Colosimo, S., Tan, G. D., Petroni, M. L., Marchesini, G., & Tomlinson, J. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.12.010 · Cited by 25 · see citing works

NAFLD and type 2 diabetes: A practical guide for the joint management

Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.12.002 · Cited by 23 · see citing works

Review of current and new drugs for the treatment of metabolic-associated fatty liver disease

Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 24 · see citing works

Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease

Song, T., Chen, S., Zhao, H., Wang, F., Song, H., Tian, D., Yang, Q., & Qi, L. (2021) · Hepatology Research · doi:10.1111/hepr.13645 · Cited by 23 · see citing works

Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting

Allen, A. M., Charlton, M., Cusi, K. J., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2325332 · Cited by 22 · see citing works

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Jung, C., & Mok, J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.18 · Cited by 22 · see citing works

Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes

Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020) · Diabetic Medicine · doi:10.1111/dme.14356 · Cited by 21 · see citing works

Anti-diabetic drugs and NASH: from current options to promising perspectives

Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 21 · see citing works

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 127 · see citing works

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease

Inoue, M., Hayashi, A., Taguchi, T., Arai, R., Sasaki, S., Takano, K., Inoue, Y., & Shichiri, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12980 · Cited by 105 · see citing works

Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes

Schernthaner, G., Lavalle-Gonzalez, F. J., Davidson, J. A., Jodon, H., Vijapurkar, U., Qiu, R., & Canovatchel, W. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1210988 · Cited by 13 · see citing works

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

Cefalu, W. T., Stenlöf, K., Leiter, L. A., Wilding, J. P. H., Blonde, L., Polidori, D., Xie, J., Sullivan, D., Usiskin, K., Canovatchel, W. J., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3547-2 · Cited by 139 · see citing works

Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease.

Gautam, A., Agrawal, P. K., Doneria, J., & Nigam, A. K. (2018) · PubMed · Cited by 17 · see citing works